These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 360234)

  • 1. Baclofen in the treatment of schizophrenia: a pilot study.
    Schöpf J; Hucker H
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Mar; 10(2):89-91. PubMed ID: 360234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baclofen (para-chlorphenyl-GABA) in schizophrenia.
    Beckmann H; Frische M; Rüther E; Zimmer R
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Jan; 10(1):26-31. PubMed ID: 329292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baclofen in chronic schizophrenia.
    Bigelow LB
    Psychopharmacol Bull; 1977 Jan; 13(1):4-5. PubMed ID: 319473
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neuroleptic effect of baclofen in chronic schizophrenia (author's transl)].
    Kuhn R
    Arzneimittelforschung; 1976; 26(6):1187. PubMed ID: 989412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baclofen in the treatment of tardive dyskinesia and schizophrenia.
    Simpson GM; Lee JH; Shrivastava RK; Branchey MH
    Psychopharmacol Bull; 1978 Apr; 14(2):16-8. PubMed ID: 349598
    [No Abstract]   [Full Text] [Related]  

  • 6. Baclofen treatment for chronic posttraumatic stress disorder.
    Drake RG; Davis LL; Cates ME; Jewell ME; Ambrose SM; Lowe JS
    Ann Pharmacother; 2003 Sep; 37(9):1177-81. PubMed ID: 12921495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients].
    Bralet MC; Yon V; Loas G; Noisette C
    Encephale; 2000; 26(6):32-41. PubMed ID: 11217537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
    Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction and evaluation criteria in perazine therapy of acute schizophrenics: psychopathological results.
    Schied HW; Rein W; Straube E; Jung H; Breyer-Pfaff U
    Pharmacopsychiatria; 1983 Sep; 16(5):152-9. PubMed ID: 6140694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Social integration of long-term paraphrenic patients with low-dose depot neuroleptic medication].
    Lesch OM; Dietzel-Rogan M; Musalek M; Rajna P; Rustembegovich A; Schjerve M; Walter H
    Psychiatr Prax; 1985 Mar; 12(2):63-8. PubMed ID: 3887443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher than usual dosage of haloperidol: a pilot study in chronic schizophrenics.
    Pacquay M; Brasseur F
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):46-9. PubMed ID: 798190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromocriptine in augmentation of antipsychotic response in chronic schizophrenia: a negative pilot report.
    Wells BG; Chu CC; Abi-Darghum A; Saini TS
    Pharmacopsychiatry; 1991 Jul; 24(4):118-20. PubMed ID: 1684441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open study of mesoridazine (Serentil) in chronic schizophrenics.
    Aguilar SJ
    Dis Nerv Syst; 1975 Sep; 36(9):484-9. PubMed ID: 1175465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biochemical effects of nicergoline in chronic schizophrenic patients.
    Albus M; Botschev C; Müller-Spahn F; Naber D; Münch U; Ackenheil M
    Pharmacopsychiatry; 1986 May; 19(3):101-5. PubMed ID: 3725889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lioresal (baclofen) treatment of spasticity in multiple sclerosis.
    Basmajian JV
    Am J Phys Med; 1975 Aug; 54(4):175-7. PubMed ID: 1098477
    [No Abstract]   [Full Text] [Related]  

  • 18. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
    Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS
    Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia.
    Yamagami S; Soejima K
    Drugs Exp Clin Res; 1989; 15(4):171-6. PubMed ID: 2570687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loxapine succinate: a controlled double-blind study in chronic schizophrenia.
    Schiele BC
    Dis Nerv Syst; 1975 Jul; 36(7):361-4. PubMed ID: 1097221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.